ClinicalTrials.gg
CompletedNCT05279131Updated Jan 23, 2024Results posted

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

A Phase 3 interventional study of Tirbanibulin ointment 1% in Keratosis, Actinic, sponsored by Almirall, S.A.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..

Enrollment
10th of 12
105 · median 307
Started
2022
with 3 others
Phase 3
7 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 in phase 3, and was the 10th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Keratosis, Actinic by Almirall, S.A. as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.

03

Conditions studied

  • Keratosis, Actinic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a treatment field (TF) on the face or balding scalp (excluding lips, eyelids, and inside nostrils and ears) that measures approximately 100 cm\^2 (eg, mid face) and contains 4 to 12 clinically typical, visible, and discrete actinic keratosis (AK) lesions within the TF
  • Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp during the study
  • Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provided written in accordance with institutional and regulatory guidelines

Exclusion criteria

Exclusion Criteria:

  • Presence in the TF of

    1. Clinically atypical and/or rapidly changing AK lesions in the TF
    2. Hyperkeratotic or hypertrophic lesions, recalcitrant disease (had cryosurgery on 2 previous occasions) and/or cutaneous horn
    3. Confluent AK lesions (ie, non-discrete lesions defined as per inclusion criteria)
    4. History of invasive squamous cell carcinoma (SCC), Bowen's disease, basal cell carcinoma (BCC), or other malignant tumors in the TF
    5. Any other dermatological disease that causes difficulty with examination
  • Previous treatment with tirbanibulin ointment 1%.
  • Anticipated need for inpatient hospitalization or inpatient surgery from Day 1 to Day 57
  • Treatment with 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the TF or within 2 cm of the TF, within 8 weeks prior to the Screening visit
  • Use of systemic retinoids (eg, isotretinoin, acitretin, bexarotene) within 6 months prior to the Screening visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Tirbanibulin (Klisyri®)

    Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of Actinic Keratosis (AK) lesions in the treatment field (TF) until completion of the response assessment period at Day 57.

    Drug: Tirbanibulin ointment 1%

Interventions

  • Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.

06

What researchers measure

Primary outcomes

  1. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5

    Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 5 were reported.

    Time frame: Baseline, Day 5

  2. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8

    Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 8 were reported.

    Time frame: Baseline, Day 8

  3. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15

    Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 15 were reported.

    Time frame: Baseline, Day 15

  4. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29

    Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 29 were reported.

    Time frame: Baseline, Day 29

  5. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57

    Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 57 were reported.

    Time frame: Baseline, Day 57

  6. Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)

    Maximum local tolerability score post baseline was defined as the highest grade of any LSR reported at any post-baseline visits for a participant. Local tolerability score was assessed for signs erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. If a participant maximum individual sign local tolerability score stayed at 0 throughout the study, the participant was considered censored at last local tolerability score observation. Number of participants with maximum local tolerability score for each individual signs including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were reported.

    Time frame: Baseline, Maximum post-baseline (up to Day 57)

  7. Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration

    Time to maximum local tolerability score (in days) for each individual sign was calculated as \[Date of first post-baseline occurrence of maximum local tolerability score for this individual sign - Date of first dose\]. If a participant maximum individual sign LTA score stays at 0 throughout the study, the participants was considered censored at their last LTA score observation. Maximum local tolerability score was assessed for each signs using a 4 - point scale of 0 - 3, where 0 = absent, 1= mild, 2= moderate and 3 = severe. The higher score indicates severe symptoms. Time to maximum local tolerability score for erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration was reported.

    Time frame: Baseline up to Day 57

  8. Local Tolerability Signs Total Composite Score by Visit at Day 5

    Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score assessed from baseline up to Day 5 was reported.

    Time frame: Baseline, Day 5

  9. Local Tolerability Signs Total Composite Score by Visit at Day 8

    Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 8 was reported.

    Time frame: Baseline, Day 8

  10. Local Tolerability Signs Total Composite Score by Visit at Day 15

    Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 15 was reported.

    Time frame: Baseline, Day 15

  11. Local Tolerability Signs Total Composite Score by Visit at Day 29

    Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 29 was reported.

    Time frame: Baseline, Day 29

  12. Local Tolerability Signs Total Composite Score by Visit at Day 57

    Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 57 was reported.

    Time frame: Baseline, Day 57

  13. Maximum Local Tolerability Signs Total Composite Score Post Baseline

    The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Maximum local tolerability signs total composite score post baseline was reported.

    Time frame: Baseline, Maximum post-baseline (up to Day 57)

  14. Time to Maximum Local Tolerability Total Composite Score

    Time to maximum composite local tolerability score (in days) was calculated as (Date of first post-baseline occurrence of maximum composite local tolerability score - Date of first dose). The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. If a participant's maximum composite local tolerability score stays at 0 throughout the study, the participant was considered censored at their last local tolerability score observation. Time to maximum local tolerability total composite score was reported.

    Time frame: Baseline up to Day 57

  15. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5

    Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 5 was reported.

    Time frame: Baseline, Day 5

  16. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8

    Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 8 was reported.

    Time frame: Baseline, Day 8

  17. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15

    Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 15 was reported.

    Time frame: Baseline, Day 15

  18. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29

    Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 29 was reported.

    Time frame: Baseline, Day 29

  19. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57

    Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 57 was reported.

    Time frame: Baseline, Day 57

  20. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)

    TEAEs were defined as either those adverse events (AEs) with an onset after dosing or those pre-existing conditions that worsened after dosing. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An SAE with any untoward medical occurrence that at any dose, resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in the child of a participant who was exposed to the study drug, or any other medically important event that may jeopardize the patient or require intervention to prevent one of the other outcomes. AESI's included in this study were skin cancers (including basal cell carcinoma, squamous cell carcinoma, and melanoma) based on their relevance for the current intended use. TEAEs included both serious and non-serious AEs.

    Time frame: Baseline up to Day 57

  21. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Laboratory parameters included blood chemistry, hamatology, and urinalysis. Clinically significant laboratory abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in laboratory parameters (included hematology, blood chemistry and urinalysis) were reported.

    Time frame: Baseline up to Day 57

  22. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinically significant vital signs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in vital signs were reported.

    Time frame: Baseline up to Day 57

  23. Number of Participants With Clinically Significant Abnormalities in Physical Examination

    Physical examination included weight and height measurements. Clinically significant physical examination abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in physical examination were reported.

    Time frame: Baseline up to Day 57

  24. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

    ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Clinically significant ECGs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in ECG were reported.

    Time frame: Baseline up to Day 57

07

Results

Posted Jan 23, 2024

Participant flow

This study was conducted at 20 sites in the United States from 28 June 2022 to 28 December 2022.

Participant flow — Overall Study
MilestoneTirbanibulin (Klisyri®)
Started105
Completed102
Not completed3
Withdrew: Lost to follow-up1
Withdrew: Death1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5

Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 5 were reported.

Time frame:
Baseline, Day 5
Reported as:
Count of participants · Participants
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Day 5: Erythema — Grade 013
At Day 5: Erythema — Grade 141
At Day 5: Erythema — Grade 244
At Day 5: Erythema — Grade 33
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Day 5: Flaking/Scaling — Grade 044
At Day 5: Flaking/Scaling — Grade 138
At Day 5: Flaking/Scaling — Grade 219
At Day 5: Flaking/Scaling — Grade 30
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Day 5: Crusting — Grade 090
At Day 5: Crusting — Grade 19
At Day 5: Crusting — Grade 22
At Day 5: Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Day 5: Swelling — Grade 073
At Day 5: Swelling — Grade 125
At Day 5: Swelling — Grade 23
At Day 5: Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Day 5: Vesiculation/Pustulation — Grade 098
At Day 5: Vesiculation/Pustulation — Grade 13
At Day 5: Vesiculation/Pustulation — Grade 20
At Day 5: Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Day 5: Erosion/Ulceration — Grade 097
At Day 5: Erosion/Ulceration — Grade 14
At Day 5: Erosion/Ulceration — Grade 20
At Day 5: Erosion/Ulceration — Grade 30
PrimaryNumber of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8

Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 8 were reported.

Time frame:
Baseline, Day 8
Reported as:
Count of participants · Participants
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Day 8: Erythema — Grade 09
At Day 8: Erythema — Grade 132
At Day 8: Erythema — Grade 257
At Day 8: Erythema — Grade 34
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Day 8: Flaking/Scaling — Grade 018
At Day 8: Flaking/Scaling — Grade 143
At Day 8: Flaking/Scaling — Grade 233
At Day 8: Flaking/Scaling — Grade 38
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Day 8: Crusting — Grade 066
At Day 8: Crusting — Grade 128
At Day 8: Crusting — Grade 28
At Day 8: Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Day 8: Swelling — Grade 075
At Day 8: Swelling — Grade 119
At Day 8: Swelling — Grade 28
At Day 8: Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Day 8: Vesiculation/Pustulation — Grade 0101
At Day 8: Vesiculation/Pustulation — Grade 11
At Day 8: Vesiculation/Pustulation — Grade 20
At Day 8: Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Day 8: Erosion/Ulceration — Grade 091
At Day 8: Erosion/Ulceration — Grade 18
At Day 8: Erosion/Ulceration — Grade 23
At Day 8: Erosion/Ulceration — Grade 30
PrimaryNumber of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15

Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 15 were reported.

Time frame:
Baseline, Day 15
Reported as:
Count of participants · Participants
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Day 15: Erythema — Grade 033
At Day 15: Erythema — Grade 161
At Day 15: Erythema — Grade 27
At Day 15: Erythema — Grade 30
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Day 15: Flaking/Scaling — Grade 054
At Day 15: Flaking/Scaling — Grade 133
At Day 15: Flaking/Scaling — Grade 213
At Day 15: Flaking/Scaling — Grade 31
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Day 15: Crusting — Grade 086
At Day 15: Crusting — Grade 112
At Day 15: Crusting — Grade 23
At Day 15: Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Day 15: Swelling — Grade 096
At Day 15: Swelling — Grade 14
At Day 15: Swelling — Grade 21
At Day 15: Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Day 15: Vesiculation/Pustulation — Grade 0101
At Day 15: Vesiculation/Pustulation — Grade 10
At Day 15: Vesiculation/Pustulation — Grade 20
At Day 15: Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Day 15: Erosion/Ulceration — Grade 0100
At Day 15: Erosion/Ulceration — Grade 10
At Day 15: Erosion/Ulceration — Grade 21
At Day 15: Erosion/Ulceration — Grade 30
PrimaryNumber of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29

Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 29 were reported.

Time frame:
Baseline, Day 29
Reported as:
Count of participants · Participants
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Day 29: Erythema — Grade 074
At Day 29: Erythema — Grade 126
At Day 29: Erythema — Grade 20
At Day 29: Erythema — Grade 30
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Day 29: Flaking/Scaling — Grade 084
At Day 29: Flaking/Scaling — Grade 116
At Day 29: Flaking/Scaling — Grade 20
At Day 29: Flaking/Scaling — Grade 30
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Day 29: Crusting — Grade 097
At Day 29: Crusting — Grade 13
At Day 29: Crusting — Grade 20
At Day 29: Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Day 29: Swelling — Grade 098
At Day 29: Swelling — Grade 12
At Day 29: Swelling — Grade 20
At Day 29: Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Day 29: Vesiculation/Pustulation — Grade 0100
At Day 29: Vesiculation/Pustulation — Grade 10
At Day 29: Vesiculation/Pustulation — Grade 20
At Day 29: Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Day 29: Erosion/Ulceration — Grade 0100
At Day 29: Erosion/Ulceration — Grade 10
At Day 29: Erosion/Ulceration — Grade 20
At Day 29: Erosion/Ulceration — Grade 30
PrimaryNumber of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57

Local tolerability score was evaluated by investigator in terms of presence and absence of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration signs and its severity in the areas of body where medication was applied. These symptoms were assessed by using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. Number of participants categorized by local tolerability score by visit for each individual signs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) at Day 57 were reported.

Time frame:
Baseline, Day 57
Reported as:
Count of participants · Participants
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Day 57: Erythema — Grade 095
At Day 57: Erythema — Grade 17
At Day 57: Erythema — Grade 20
At Day 57: Erythema — Grade 30
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Day 57: Flaking/Scaling — Grade 099
At Day 57: Flaking/Scaling — Grade 13
At Day 57: Flaking/Scaling — Grade 20
At Day 57: Flaking/Scaling — Grade 30
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Day 57: Crusting — Grade 0102
At Day 57: Crusting — Grade 10
At Day 57: Crusting — Grade 20
At Day 57: Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Day 57: Swelling — Grade 0102
At Day 57: Swelling — Grade 10
At Day 57: Swelling — Grade 20
At Day 57: Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Day 57: Vesiculation/Pustulation — Grade 0102
At Day 57: Vesiculation/Pustulation — Grade 10
At Day 57: Vesiculation/Pustulation — Grade 20
At Day 57: Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Day 57: Erosion/Ulceration — Grade 0102
At Day 57: Erosion/Ulceration — Grade 10
At Day 57: Erosion/Ulceration — Grade 20
At Day 57: Erosion/Ulceration — Grade 30
PrimaryNumber of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)

Maximum local tolerability score post baseline was defined as the highest grade of any LSR reported at any post-baseline visits for a participant. Local tolerability score was assessed for signs erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration using a 4 - point grade scale of 0 - 3, where a score of 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). The higher score indicates severe symptoms. If a participant maximum individual sign local tolerability score stayed at 0 throughout the study, the participant was considered censored at last local tolerability score observation. Number of participants with maximum local tolerability score for each individual signs including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were reported.

Time frame:
Baseline, Maximum post-baseline (up to Day 57)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)
ParticipantsTirbanibulin (Klisyri®)
Baseline: Erythema — Grade 081
Baseline: Erythema — Grade 119
Baseline: Erythema — Grade 25
Baseline: Erythema — Grade 30
At Maximum post-baseline (up to Day 57): Erythema — Grade 04
At Maximum post-baseline (up to Day 57): Erythema — Grade 127
At Maximum post-baseline (up to Day 57): Erythema — Grade 266
At Maximum post-baseline (up to Day 57): Erythema — Grade 36
Baseline: Flaking/Scaling — Grade 084
Baseline: Flaking/Scaling — Grade 117
Baseline: Flaking/Scaling — Grade 24
Baseline: Flaking/Scaling — Grade 30
At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 016
At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 134
At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 244
At Maximum post-baseline (up to Day 57): Flaking/Scaling — Grade 39
Baseline: Crusting — Grade 0103
Baseline: Crusting — Grade 12
Baseline: Crusting — Grade 20
Baseline: Crusting — Grade 30
At Maximum post-baseline (up to Day 57): Crusting — Grade 058
At Maximum post-baseline (up to Day 57): Crusting — Grade 134
At Maximum post-baseline (up to Day 57): Crusting — Grade 211
At Maximum post-baseline (up to Day 57): Crusting — Grade 30
Baseline: Swelling — Grade 0105
Baseline: Swelling — Grade 10
Baseline: Swelling — Grade 20
Baseline: Swelling — Grade 30
At Maximum post-baseline (up to Day 57): Swelling — Grade 064
At Maximum post-baseline (up to Day 57): Swelling — Grade 128
At Maximum post-baseline (up to Day 57): Swelling — Grade 211
At Maximum post-baseline (up to Day 57): Swelling — Grade 30
Baseline: Vesiculation/Pustulation — Grade 0105
Baseline: Vesiculation/Pustulation — Grade 10
Baseline: Vesiculation/Pustulation — Grade 20
Baseline: Vesiculation/Pustulation — Grade 30
At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 099
At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 14
At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 20
At Maximum post-baseline (up to Day 57): Vesiculation/Pustulation — Grade 30
Baseline: Erosion/Ulceration — Grade 0105
Baseline: Erosion/Ulceration — Grade 10
Baseline: Erosion/Ulceration — Grade 20
Baseline: Erosion/Ulceration — Grade 30
At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 090
At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 19
At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 24
At Maximum post-baseline (up to Day 57): Erosion/Ulceration — Grade 30
PrimaryTime to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration

Time to maximum local tolerability score (in days) for each individual sign was calculated as \[Date of first post-baseline occurrence of maximum local tolerability score for this individual sign - Date of first dose\]. If a participant maximum individual sign LTA score stays at 0 throughout the study, the participants was considered censored at their last LTA score observation. Maximum local tolerability score was assessed for each signs using a 4 - point scale of 0 - 3, where 0 = absent, 1= mild, 2= moderate and 3 = severe. The higher score indicates severe symptoms. Time to maximum local tolerability score for erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration was reported.

Time frame:
Baseline up to Day 57
Reported as:
Mean · Days
Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration
DaysTirbanibulin (Klisyri®)
Erythema4.0 (4 to 14)
Flaking/Scaling7.0 (4 to 15)
Crusting7.0 (4 to 28)
Swelling4.0 (4 to 12)
Vesiculation/Pustulation4.0 (4 to 7)
Erosion/Ulceration7.0 (4 to 14)
PrimaryLocal Tolerability Signs Total Composite Score by Visit at Day 5

Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score assessed from baseline up to Day 5 was reported.

Time frame:
Baseline, Day 5
Reported as:
Mean · Score on a scale
Local Tolerability Signs Total Composite Score by Visit at Day 5
Score on a scaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Day 52.6 ± 1.67
PrimaryLocal Tolerability Signs Total Composite Score by Visit at Day 8

Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 8 was reported.

Time frame:
Baseline, Day 8
Reported as:
Mean · Score on a Scale
Local Tolerability Signs Total Composite Score by Visit at Day 8
Score on a ScaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Day 83.8 ± 2.25
PrimaryLocal Tolerability Signs Total Composite Score by Visit at Day 15

Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 15 was reported.

Time frame:
Baseline, Day 15
Reported as:
Mean · Score on a Scale
Local Tolerability Signs Total Composite Score by Visit at Day 15
Score on a ScaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Day 151.6 ± 1.46
PrimaryLocal Tolerability Signs Total Composite Score by Visit at Day 29

Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 29 was reported.

Time frame:
Baseline, Day 29
Reported as:
Mean · Score on a Scale
Local Tolerability Signs Total Composite Score by Visit at Day 29
Score on a ScaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Day 290.5 ± 0.80
PrimaryLocal Tolerability Signs Total Composite Score by Visit at Day 57

Local tolerability signs composite score by visit was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Local tolerability signs total composite score by visit at Day 57 was reported.

Time frame:
Baseline, Day 57
Reported as:
Mean · Score on a Scale
Local Tolerability Signs Total Composite Score by Visit at Day 57
Score on a ScaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Day 570.1 ± 0.36
PrimaryMaximum Local Tolerability Signs Total Composite Score Post Baseline

The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. Maximum local tolerability signs total composite score post baseline was reported.

Time frame:
Baseline, Maximum post-baseline (up to Day 57)
Reported as:
Mean · Score on a scale
Maximum Local Tolerability Signs Total Composite Score Post Baseline
Score on a scaleTirbanibulin (Klisyri®)
Baseline0.5 ± 1.06
At Maximum post-baseline (up to Day 57)4.1 ± 2.12
PrimaryTime to Maximum Local Tolerability Total Composite Score

Time to maximum composite local tolerability score (in days) was calculated as (Date of first post-baseline occurrence of maximum composite local tolerability score - Date of first dose). The maximum local tolerability signs composite score across visits was derived as the maximum local tolerability composite score observed post-baseline. Local tolerability signs composite score was defined as the sum of the scores graded from 0 (absent) to 3 (severe) on all six individual tolerability sign categories - erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration which gave total composite score ranged from 0 to 18. The higher score indicates severe symptoms. If a participant's maximum composite local tolerability score stays at 0 throughout the study, the participant was considered censored at their last local tolerability score observation. Time to maximum local tolerability total composite score was reported.

Time frame:
Baseline up to Day 57
Reported as:
Median · Days
Time to Maximum Local Tolerability Total Composite Score
DaysTirbanibulin (Klisyri®)
Time to Maximum Local Tolerability Total Composite Score7.0 (6.01 to 7.31)
PrimaryNumber of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5

Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 5 was reported.

Time frame:
Baseline, Day 5
Reported as:
Count of participants · Participants
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5
ParticipantsTirbanibulin (Klisyri®)
Baseline: Hypopigmentation Presence22
Baseline: Hypopigmentation Absence83
At Day 5: Hypopigmentation Presence22
At Day 5: Hypopigmentation Absence78
Baseline: Hyperpigmentation Presence28
Baseline: Hyperpigmentation Absence77
At Day 5: Hyperpigmentation Presence26
At Day 5: Hyperpigmentation Absence74
Baseline: Scarring Presence12
Baseline: Scarring Absence93
At Day 5: Scarring Presence12
At Day 5: Scarring Absence88
PrimaryNumber of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8

Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 8 was reported.

Time frame:
Baseline, Day 8
Reported as:
Count of participants · Participants
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8
ParticipantsTirbanibulin (Klisyri®)
Baseline: Hypopigmentation Presence22
Baseline: Hypopigmentation Absence83
At Day 8: Hypopigmentation Presence21
At Day 8: Hypopigmentation Absence80
Baseline: Hyperpigmentation Presence28
Baseline: Hyperpigmentation Absence77
At Day 8: Hyperpigmentation Presence23
At Day 8: Hyperpigmentation Absence78
Baseline: Scarring Presence12
Baseline: Scarring Absence93
At Day 8: Scarring Presence13
At Day 8: Scarring Absence88
PrimaryNumber of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15

Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 15 was reported.

Time frame:
Baseline, Day 15
Reported as:
Count of participants · Participants
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15
ParticipantsTirbanibulin (Klisyri®)
Baseline: Hypopigmentation Presence22
Baseline: Hypopigmentation Absence83
At Day 15: Hypopigmentation Presence21
At Day 15: Hypopigmentation Absence80
Baseline: Hyperpigmentation Presence28
Baseline: Hyperpigmentation Absence77
At Day 15: Hyperpigmentation Presence20
At Day 15: Hyperpigmentation Absence81
Baseline: Scarring Presence12
Baseline: Scarring Absence93
At Day 15: Scarring Presence11
At Day 15: Scarring Absence90
PrimaryNumber of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29

Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 29 was reported.

Time frame:
Baseline, Day 29
Reported as:
Count of participants · Participants
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29
ParticipantsTirbanibulin (Klisyri®)
Baseline: Hypopigmentation Presence22
Baseline: Hypopigmentation Absence83
At Day 29: Hypopigmentation Presence20
At Day 29: Hypopigmentation Absence80
Baseline: Hyperpigmentation Presence28
Baseline: Hyperpigmentation Absence77
At Day 29: Hyperpigmentation Presence16
At Day 29: Hyperpigmentation Absence84
Baseline: Scarring Presence12
Baseline: Scarring Absence93
At Day 29: Scarring Presence10
At Day 29: Scarring Absence90
PrimaryNumber of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57

Absence and presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment field by visit at Day 57 was reported.

Time frame:
Baseline, Day 57
Reported as:
Count of participants · Participants
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57
ParticipantsTirbanibulin (Klisyri®)
Baseline: Hypopigmentation Presence22
Baseline: Hypopigmentation Absence83
At Day 57: Hypopigmentation Presence18
At Day 57: Hypopigmentation Absence84
Baseline: Hyperpigmentation Presence28
Baseline: Hyperpigmentation Absence77
At Day 57: Hyperpigmentation Presence16
At Day 57: Hyperpigmentation Absence86
Baseline: Scarring Presence12
Baseline: Scarring Absence93
At Day 57: Scarring Presence9
At Day 57: Scarring Absence93
PrimaryNumber of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)

TEAEs were defined as either those adverse events (AEs) with an onset after dosing or those pre-existing conditions that worsened after dosing. An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An SAE with any untoward medical occurrence that at any dose, resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in the child of a participant who was exposed to the study drug, or any other medically important event that may jeopardize the patient or require intervention to prevent one of the other outcomes. AESI's included in this study were skin cancers (including basal cell carcinoma, squamous cell carcinoma, and melanoma) based on their relevance for the current intended use. TEAEs included both serious and non-serious AEs.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)
ParticipantsTirbanibulin (Klisyri®)
Participants with TEAEs29
Participants with Serious TEAEs2
Participants with AESIs2
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Laboratory parameters included blood chemistry, hamatology, and urinalysis. Clinically significant laboratory abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in laboratory parameters (included hematology, blood chemistry and urinalysis) were reported.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsTirbanibulin (Klisyri®)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinically significant vital signs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in vital signs were reported.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsTirbanibulin (Klisyri®)
Number of Participants With Clinically Significant Abnormalities in Vital Signs1
PrimaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination

Physical examination included weight and height measurements. Clinically significant physical examination abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in physical examination were reported.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination
ParticipantsTirbanibulin (Klisyri®)
Number of Participants With Clinically Significant Abnormalities in Physical Examination1
PrimaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Clinically significant ECGs abnormalities assessment was based on Investigator interpretation. Number of participants with clinically significant abnormalities in ECG were reported.

Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
ParticipantsTirbanibulin (Klisyri®)
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)1

Adverse events

Collected over Baseline up to Day 57. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirbanibulin (Klisyri®)1/105 (1%)2/105 (1.9%)29/105 (27.6%)
Most frequent serious events
Most frequent serious events
EventTirbanibulin (Klisyri®)
TachycardiaCardiac disorders1/105
AstheniaGeneral disorders1/105
Failure to thriveMetabolism and nutrition disorders1/105
HypercalcaemiaMetabolism and nutrition disorders1/105
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/105
EncephalopathyNervous system disorders1/105
Acute kidney injuryRenal and urinary disorders1/105
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTirbanibulin (Klisyri®)
Application site pruritusGeneral disorders11/105
Application site painGeneral disorders9/105
DizzinessNervous system disorders2/105
ParaesthesiaNervous system disorders2/105
Atrial fibrillationCardiac disorders1/105
Application site bruiseGeneral disorders1/105
Application site drynessGeneral disorders1/105
Application site hypoaesthesiaGeneral disorders1/105
Oedema peripheralGeneral disorders1/105
TendernessGeneral disorders1/105

Baseline characteristics

The safety population included all enrolled participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Tirbanibulin (Klisyri®)
Mean69.1 ± 8.90
Sex: Female, Male
Sex: Female, Male(Participants)Tirbanibulin (Klisyri®)
Female33
Male72
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tirbanibulin (Klisyri®)
Hispanic or Latino7
Not Hispanic or Latino98
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tirbanibulin (Klisyri®)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White105
More than one race0
Unknown or Not Reported0
Number of AK lesions at baseline
Number of AK lesions at baseline(Number of AK lesions)Tirbanibulin (Klisyri®)
Mean7.7 ± 2.72
08

Study locations

7 sites
  • Almirall Investigation Site 7
    Hot Springs, Arkansas 71913, United States
  • Almirall Investigation Site 6
    Encinitas, California 92024, United States
  • Almirall Investigation Site 3
    Sweetwater, Florida 33172, United States
  • Almirall Investigation Site 5
    Rolling Meadows, Illinois 60008, United States
  • Almirall Investigation Site 4
    Austin, Texas 78759, United States
  • Almirall Investigational Site 1
    College Station, Texas 77845, United States
  • Almirall Investigation Site 2
    San Antonio, Texas 78213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Dec 2022, 6 months.

Results were first posted in Jan 2024, 1 year after primary completion.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2022
First posted
Mar 15, 2022
StartActual
Jun 28, 2022
Primary completionActual
Dec 28, 2022
CompletionActual
Dec 28, 2022
Results first posted
Jan 23, 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05279131
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Jun 28, 2022
Primary completion
Dec 28, 2022
Completion
Dec 28, 2022
Results posted
Jan 23, 2024
Last update
Jan 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion